- Home
- CERS
CERS
Cerus Corporation
as 07-26-2024 4:00pm EST
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Upcoming Earnings Alert:
Get ready for potential market movements as Cerus Corporation CERS prepares to release earnings report on 01 Aug 2024.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | CONCORD |
| Market Cap: | 366.1M | IPO Year: | 1997 |
| Target Price: | $3.25 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.21 - $3.08 | Next Earning Date: | 08-01-2024 |
| Revenue: | $191,716,000 | Revenue Growth: | 4.32% |
| Revenue Growth (this year): | 3.72% | Revenue Growth (next year): | 13.56% |
Stock Insider Trading Activity of Cerus Corporation (CERS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shan Hua | CERS | Director | May 13 '24 | Buy | $1.99 | 2,500 | $4,974.75 | 32,386 | SEC Form 4 |
| NACHTSHEIM JAMI K | CERS | Director | May 10 '24 | Buy | $1.79 | 2,000 | $3,578.20 | 108,362 | SEC Form 4 |
| Swisher Daniel N JR | CERS | Director | May 9 '24 | Buy | $1.88 | 2,500 | $4,688.75 | 107,045 | SEC Form 4 |
| Witney Frank | CERS | Director | May 9 '24 | Buy | $1.89 | 20,000 | $37,800.00 | 180,059 | SEC Form 4 |
| Jensen Chrystal | CERS | Chief Legal Officer | Mar 12 '24 | Sell | $1.97 | 17,824 | $35,191.71 | 490,912 | SEC Form 4 |
| Jensen Chrystal | CERS | Chief Legal Officer | Mar 12 '24 | Sell | $2.06 | 17,460 | $35,915.22 | 508,736 | SEC Form 4 |
| Jayaraman Vivek K | CERS | Chief Operating Officer | Mar 12 '24 | Sell | $2.06 | 26,247 | $53,990.08 | 905,447 | SEC Form 4 |
| Jayaraman Vivek K | CERS | Chief Operating Officer | Mar 12 '24 | Sell | $1.97 | 26,794 | $52,902.07 | 878,653 | SEC Form 4 |
| Benjamin Richard J | CERS | Chief Medical Officer | Mar 12 '24 | Sell | $2.06 | 17,377 | $35,744.49 | 477,350 | SEC Form 4 |
| Benjamin Richard J | CERS | Chief Medical Officer | Mar 12 '24 | Sell | $1.97 | 17,738 | $35,021.91 | 459,612 | SEC Form 4 |
| Green Kevin Dennis | CERS | Chief Financial Officer | Mar 12 '24 | Sell | $2.02 | 21,058 | $42,438.19 | 640,247 | SEC Form 4 |
| Green Kevin Dennis | CERS | Chief Financial Officer | Mar 12 '24 | Sell | $1.97 | 21,497 | $42,443.68 | 618,750 | SEC Form 4 |
| Moore Carol | CERS | SVP Reg. & Quality | Mar 12 '24 | Sell | $2.06 | 10,203 | $20,987.57 | 501,039 | SEC Form 4 |
| Moore Carol | CERS | SVP Reg. & Quality | Mar 12 '24 | Sell | $1.97 | 10,416 | $20,565.35 | 490,623 | SEC Form 4 |
| Greenman William Mariner | CERS | President and CEO | Mar 12 '24 | Sell | $2.06 | 62,315 | $128,181.96 | 3,244,892 | SEC Form 4 |
| Greenman William Mariner | CERS | President and CEO | Mar 12 '24 | Sell | $2.02 | 63,611 | $128,195.25 | 3,181,281 | SEC Form 4 |
| CORASH LAURENCE M | CERS | Chief Scientific Officer | Mar 12 '24 | Sell | $2.06 | 14,067 | $28,935.82 | 2,354,100 | SEC Form 4 |
| CORASH LAURENCE M | CERS | Chief Scientific Officer | Mar 12 '24 | Sell | $1.97 | 14,360 | $28,352.38 | 2,339,740 | SEC Form 4 |
| Benjamin Richard J | CERS | Chief Medical Officer | Mar 8 '24 | Sell | $2.40 | 29,378 | $70,457.26 | 478,061 | SEC Form 4 |
| BJERKHOLT ERIC | CERS | Director | Dec 13 '23 | Buy | $1.62 | 10,000 | $16,200.00 | 142,133 | SEC Form 4 |
Latest Cerus Corporation News
CERS Breaking Stock News: Dive into CERS Ticker-Specific Updates for Smart Investing
Business Wire
8 days ago
Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024
Business Wire
24 days ago
Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors
Business Wire
a month ago
Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion
Simply Wall St.
a month ago
Cerus (NASDAQ:CERS) shareholders have endured a 70% loss from investing in the stock three years ago
Business Wire
a month ago
Cerus Corporation Celebrates World Blood Donor Day 2024
CNW Group
2 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
2 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
2 months ago
Seoul says it will resume loudspeaker propaganda against North
Compare CERS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CERS Cerus Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.